(Q47575476)

4 February 2018

title

Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. (English)

1 reference

4 February 2018

1 reference

Thomas J Hope

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

11 October 2011

1 reference

4 February 2018

published in

Nature Medicine

1 reference

4 February 2018

volume

17

1 reference

4 February 2018

page(s)

1195-1197

1 reference

4 February 2018

issue

10

1 reference

4 February 2018

https://scigraph.springernature.com/pub.10.1038/nm.2528

exact match

0 references

cites work

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

1 reference

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

21 January 2018

1 reference

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

21 January 2018

1 reference

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

21 January 2018

1 reference

Correlates of protection induced by vaccination

21 January 2018

1 reference

Broad neutralization coverage of HIV by multiple highly potent antibodies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21988997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21988997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NM.2528

1 reference

4 February 2018

PubMed ID

21988997

1 reference

4 February 2018